Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1633 1634
This examiner grants 28% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18272355 | HIV Pseudovirus Particles and Method for Preparing the Same | Final Rejection | BOE Technology Group Co., Ltd. |
| 17357652 | CELL TRANSPLANTATION KIT, METHOD FOR PRODUCING SAC-SHAPED STRUCTURE, AND THERAPEUTIC AGENT FOR DIABETES | Final Rejection | FUJIFILM Corporation |
| 17904565 | Adeno-Associated Viral (AAV)-Mediated Sgpl1 Gene Therapy For Treatment Of Sphingosine-1-Phosphate Lyase Insufficiency Syndrome (SPLIS) | Final Rejection | The Regents of the University of California |
| 17759539 | NON-HUMAN ANIMALS COMPRISING A HUMANIZED TTR LOCUS COMPRISING A V30M MUTATION AND METHODS OF USE | Final Rejection | Regeneron Pharmaceuticals, Inc. |
| 17442471 | ENGINEERED MRNA SEQUENCES AND USES THEREOF | Non-Final OA | Ohio State Innovation Foundation |
| 17924539 | DISEASE CORRECTION BY DELIVERY OF AAV8 VECTORS EXPRESSING CODON OPTIMIZED NAGLU | Final Rejection | University of Florida Research Foundation, Incorporated |
| 17922174 | MACHINE GUIDED DIRECTED EVOLUTION OF RAAV COMBINATORIAL CAPSID LIBRARIES | Non-Final OA | University of Florida Research Foundation, Incorporated |
| 17772266 | GENE THERAPY VECTORS | Non-Final OA | University of Florida Research Foundation, Incorporated |
| 17801815 | NOVEL TYPE IV AND TYPE I CRISPR-CAS SYSTEMS AND METHODS OF USE THEREOF | Final Rejection | MASSACHUSETTS INSTITUTE OF TECHNOLOGY |
| 17768146 | MODIFIED STEM CELLS AND METHODS OF USE THEREOF | Non-Final OA | Arizona Board of Regents on behalf of the University of Arizona |
| 18100028 | WATER-BASED HYPOTONIC LYSIS METHOD FOR ADENO-ASSOCIATED VIRUS PURIFICATION | Final Rejection | UNIVERSITY OF SOUTH CAROLINA |
| 17909187 | METHODS OF CONTROLLING BODYWEIGHT BY MODULATING PHOSPHATIDYLINOSITOL 5-PHOSPHATE 4-KINASE BETA ACTIVITY | Final Rejection | University of Cincinnati |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy